Onno van de Stolpe

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.

Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.